Valeant Pharmaceuticals International Inc. plans to ask lenders to loosen restrictions on its debt load shortly, Chief Executive Officer Joe Papa said Tuesday on a call discussing second-quarter results.
While the company is currently in compliance with financial maintenance covenants, "our cushion" is not as large as we would like it to be, Papa said. This will be the company's second time seeking covenant relief from lenders this year. In April, Valeant got creditors to relax its interest coverage maintenance covenant as part of a broader effort to amend its credit agreement and waive a default.
Some of Valeant's lenders are willing to loosen terms if they can secure a generous fee or a higher interest rate from the company, according to people with knowledge of the matter.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
- Exclusive discounts on ALM and Treasury & Risk events.
- Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.
*May exclude premium content
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
